References question 1

Acar, A. et al., 2016. A role for notch signalling in breast cancer and endocrine resistance. *Stem Cells International*, 2016, pp.1–6.

Baselga, J., 2011. Targeting the phosphoinositide-3 (pi3) kinase pathway in breast cancer. *The Oncologist*, 16(S1), pp.12–19.

DeSantis, C. et al., 2013. Breast cancer statistics, 2013. *CA: A Cancer Journal for Clinicians*, 64(1), pp.52–62.

Hinz, N. & Jücker, M., 2019. Distinct functions of Akt isoforms in breast cancer: A comprehensive review. *Cell Communication and Signaling*, 17(1).

Horrocks J, LSC202, 2021-22

Kamaruzman, N.I. et al., 2019. Oncogenic signaling in tumorigenesis and applications of Sirna Nanotherapeutics in breast cancer. *Cancers*, 11(5), p.632.

Kasper, M. et al., 2009. Hedgehog signalling in breast cancer. *Carcinogenesis*, 30(6), pp.903–911.

Nola S, Sin S, Bonin F, Lidereau R, Driouch K. A methodological approach to unravel organ-specific breast cancer metastasis. *J Mammary Gland Biol Neoplasia.* 2012;17(2):135–145

Palomeras, S., Ruiz-Martínez, S. & Puig, T., 2018. Targeting breast cancer stem cells to overcome treatment resistance. *Molecules*, 23(9), p.2193.

Song, K. & Farzaneh, M., 2021. Signaling pathways governing breast cancer stem cells behavior. *Stem Cell Research & Therapy*, 12(1).

Xu, X. et al., 2020. Wnt signaling in breast cancer: Biological Mechanisms, challenges and opportunities. *Molecular Cancer*, 19(1).

Zhang, D. et al., 2017. The role of epithelial cell adhesion molecule N-glycosylation on apoptosis in breast cancer cells. *Tumor Biology*, 39(3), p.101042831769597.

References question 2

Anon, 2017. The Immune System Review. *Khan Academy*. Available at: https://www.khanacademy.org/science/in-in-class-12-biology-india/xc09ed98f7a9e671b:in-in-human-health-and-disease/xc09ed98f7a9e671b:in-in-

types-of-immunity-and-the-immune-system/a/hs-the-immune-system-review [Accessed January 2, 2022].

Bledsoe, K., 2011. Cell membrane structure & function. *WOU*. Available at: https://people.wou.edu/~bledsoek/102materials/102studynotes/102ch5.pdf [Accessed January 2, 2022].

Chaplin, D.D., 2010. Overview of the immune response. *Journal of Allergy and Clinical Immunology*, 125(2).

Horrocks J, LSC202, 2021-22

Steane, R., Cell recognition. *BioTopics*. Available at: https://www.biotopics.co.uk/A19/Cell_recognition.html [Accessed December 29, 2021].

References question 3

Actor, J.K. & Actor, J.K., 2012. *Elsevier's Integrated Review: Immunology and microbiology*, Philadelphia, PA: Elsevier/Saunders.

Andersen, M.H. et al., 2006. Cytotoxic T cells. *Journal of Investigative Dermatology*, 126(1), pp.32–41.

Doherty, P.C., 1980. Cytotoxic T cells. *Strategies of Immune Regulation*, pp.279–281.

Horrocks J, LSC202, 2021-22

Ito, H. & Seishima, M., 2010. Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell. *Journal of Biomedicine and Biotechnology*, 2010, pp.1–8.

Raskov, H. et al., 2020. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. *British Journal of Cancer*, 124(2), pp.359–367.

Stadtmauer, E.A. et al., 2020. CRISPR-engineered T cells in patients with refractory cancer. *Science*, 367(6481).

Steitz, J. et al., 2004. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: Implications for the pathophysiology of Vitiligo. *European Journal of Cell Biology*, 83(11-12), pp.797–803.

Wissinger, E., Cd8+ T cells. *British Society for Immunology*. Available at: https://www.immunology.org/public-information/bitesized-immunology/cells/cd8-t-cells [Accessed January 8, 2022].